Premium
STILBCESTROL DIPHOSPHATE (HONVAN) IN THE TREATMENT OF ACUTE URINARY RETENTION DUE TO PROSTATIC CARCINOMA 1
Author(s) -
Parton Ian
Publication year - 1965
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1965.tb09605.x
Subject(s) - urinary retention , medicine , urology , carcinoma , biopsy , prostate , resection , transurethral resection of the prostate , surgery , cancer
SUMMARY In a series of fifty cases (two with extreme difficulty, four with retention and overflow, forty‐four with acute retention) intravenous Honvan was given in daily doses of 500 to 1,000 mg. for five to ten days, the commonest dose being 1,000 mg. daily for five days. In thirty‐three (66 per cent.) cases no surgery was required, the other seventeen (34 per cent.) being treated by transurethral resection. Unless the patient is very old or feeble, prostatic biopsy is essential if any doubt exists about the diagnosis. Once the patient is ambulant and voiding, an oral oestrogen is usually more convenient, as well as being cheaper than an intravenous one. A trial of Honvan is specially recommended for the bad‐risk case of prostatic carcinoma with acute urinary retention.